Skip to main content

Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers

Introduction

The management of juvenile idiopathic arthritis (JIA) has been revolutionised through biologics such as etanercept (ETN), approved in the UK in 2002. Since that time, the use of other biologics in children and young people (CYP) has expanded. ETN is most often the first choice biologic in the treatment of JIA; however there may be occasions where ETN is not the preferred choice, for reasons of efficacy or safety.

Objectives

The aim of this analysis was to describe the choice of first-line biologics in UK CYP with JIA and explore possible reasons behind this choice.

Methods

Both the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN), and the Biologics for Children with Rheumatic Diseases (BCRD) study, are ongoing prospective observational cohorts, collecting detailed information on CYP starting biologics for JIA. At start of therapy, demographic and disease information is collected. Patients registered from 01/01/2010 starting a first biologic were compared between therapies using descriptive statistics. CYP starting ETN <2010 were also included to analyse changes in ETN prescribing since initial approval.

Results

To 07/04/2014, 870 patients were recruited starting a first-line biologic (123 BCRD; 747 BSPAR-ETN (582<2010, 165≥2010) (Table 1). From 2010, CYP with systemic JIA (sJIA) were almost exclusively prescribed anakinra or tocilizumab. Choice of anti-TNF therapy was largely driven by prevalence of uveitis. Compared to ETN patients pre-2010, CYP starting ETN from 2010 had shorter disease duration, less uveitis, less sJIA, and less corticosteroid use.

Table 1

Conclusion

Although ETN remains the most common biologic prescribed for JIA, there has been a shift towards the use of alternative biologics, some unlicensed, largely driven by disease subtype and the presence of uveitis. This channelling of certain children towards specific therapies is important in terms of future comparative effectiveness studies and also as a guide to ongoing research priorities within rheumatology.

Disclosure of interest

None declared.

Author information

Authors and Affiliations

Authors

Consortia

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Davies, R., Kearsley-Fleet, L., Baildam, E. et al. Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers. Pediatr Rheumatol 12, P190 (2014). https://doi.org/10.1186/1546-0096-12-S1-P190

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1546-0096-12-S1-P190

Keywords

  • Etanercept
  • Juvenile Idiopathic Arthritis
  • Uveitis
  • Rheumatic Disease
  • Tocilizumab